A Phase 3 interventional study of Bexsero® vaccine (1 dose at study month zero) and Bexsero® vaccine (2 doses 1 month apart) in Meningoccocal Disease and Meningococcal Meningitis, sponsored by Novartis Vaccines. Completed at 17 sites in 2 countries. Open to participants aged 35 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-30.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Meningitis, Meningococcal by Novartis — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Novartis.
Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 11th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2013, is one of 19 in phase 3, and was the 31st registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 32 studies in Meningitis, Meningococcal by Novartis is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 35 Months to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 21 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 851 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 707 across the 30 interventional studies, 27,895 across the 2 observational. Of the 32 that completed or were terminated, 28 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Meningitis, Meningococcal by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the Novartis meningococcal B vaccine (Bexsero®) in groups I to III of the parent V72_28 study.
This study will also explore the antibody persistence 24 to 36 months after two catch-up doses of the Novartis meningococcal B vaccine (Bexsero®) administered in children (2 to 10 years old) in group IV of the parent V72_28 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For naïve subjects newly enrolled:
Healthy infants and children according to the following age groups:
For Subjects who participated in the V72_28 study (Follow-on Subjects):
Exclusion Criteria:
For naïve subjects newly enrolled:
Known or suspected disease or impairment/alteration of the immune system resulting from (for example):
For Subjects who participated in the V72_28 study (Follow-on Subjects):
Exclusion criteria are the same as for naïve subjects, with the exception of criterion 1.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
Biological: Bexsero® vaccine (1 dose at study month zero)
In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
Biological: Bexsero® vaccine (1 dose at study month zero)
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
Biological: Bexsero® vaccine (1 dose at study month zero)
In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
Biological: Bexsero® vaccine (1 dose at study month zero)
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
Biological: Bexsero® vaccine (1 dose at study month zero)
In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
Biological: Bexsero® vaccine (2 doses 1 month apart)
Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
Biological: Bexsero® vaccine (2 doses 1 month apart)
Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
Biological: Bexsero® vaccine (2 doses 1 month apart)
Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline. The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).
Time frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis Serogroup B Strains
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.
Time frame: At 24-36 months after booster dose in the parent study: baseline for vaccine-naïve subjects
The hSBA Geometric Mean Titers (GMTs) Against N.Meningitidis Serogroup B Strains
The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.
Time frame: 24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus 1 Month After Completion of Bexsero® Vaccination Course According to Different Schedules in the Parent Study.
The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.
Time frame: At Day 1 in this study over one month after the completion of the vaccination course in the parent study
The Geometric Mean Ratio (GMR) of hSBA GMTs Against N. Meningitidis Serogroup B, 24 to 36 Months Versus Visit 1 in the Parent Study.
The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.
Time frame: At Day 1 in this study over visit 1 in the vaccination course in the parent study
Percentage of Subjects With hSBA Titers ≥4 or ≥ 5 Against N.Meningitidis Serogroup B, After Receiving Bexsero® Booster Vaccination in This Study.
The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
Time frame: At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
Percentage of Subjects With hSBA Titers ≥ 8 Against N.Meningitidis serogroupB, After Receiving Bexsero® Booster Vaccination in This Study.
The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
Time frame: At 24-36 months (Visit 1) and one month after booster vaccination (Day 31)
Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Bexsero® Vaccination in This Study.
The percentage of subjects with a four-fold rise in hSBA titers 1 month after receiving Bexsero® booster vaccination in this study to pre vaccination at visit 1 (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
Time frame: One month after booster vaccination (day 31)/24-36 months (Visit 1)
Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study
The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination (visit 2) in this study to post primary visit in the parent study V72_28(1 month after last vaccination in the parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
Time frame: From post primary visit in the parent study to visit 2 in this extension study
Percentage of Subjects With Four-fold Rise in hSBA Titers, One Month After Receiving Bexsero® Vaccination in This Study.
The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination in this study to pre primary visit in parent study V72_28 (Visit 1). This outcome measure was analysed only for subjects belonging to groups 02_2_5_V and 02_6_10_V
Time frame: From pre primary visit in the parent study (Visit 1) to visit 2 in this extension study
The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.
Time frame: At Visit 1 and one month post booster vaccination (Day 31)
The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.
Time frame: At Day 31 versus Day 1
The Geometric Mean Ratio (GMR) of hSBA Titers, One Month After Receiving Bexsero® Booster Vaccination in the Present Study.
The within-subjects GMR of hSBA antibody titers (one month post booster vaccination in this study versus 1 month post last vaccination visit (post-primary vaccination visit) in parent study V72_28.
Time frame: Visit 2 (day 31 in extension study) versus post primary vaccination visit in parent study
Percentage of Subjects With hSBA Titers ≥ 4 or ≥ 5, After Receiving Two Catch up Doses of Bexsero® Vaccination
The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.
Time frame: At Baseline and One month post second vaccination (Day 61)
Percentage of Subjects With hSBA Titers ≥ 8 , After Receiving Two Catch up Doses of Bexsero® Vaccination.
The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.
Time frame: At Baseline and One month post second vaccination (Day 61)
Percentage of Subjects With Four-fold Rise in hSBA Titers, After Receiving Two Catch up Doses of Bexsero® Vaccination.
The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.
Time frame: One month post second vaccination (Day 61)
The GMTs in Subjects Who Received Two Catch up Doses of Bexsero® Vaccination.
The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.
Time frame: At Baseline and One month post second vaccination (Day 61)
The GMRs of hSBA Titers After Two Catch up Doses of Bexsero® Vaccination Versus hSBA Titers at Baseline.
The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.
Time frame: At one month after receiving second vaccination (Day 61) versus baseline (Day 1)
Number of Subjects (35 Months to 7 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.
The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receiving Bexsero® booster vaccine in the present study.
Time frame: From day 1 (6 hr) through day 7 after vaccination
Number of Newly Recruited Subjects (Aged 35 Months to 7 Years) Reporting Solicited Local and Systemic Adverse Events After Receiving Catch-up Doses of Bexsero® Vaccine.
The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.
Time frame: From day 1 (6 hr) through day 7 after vaccination
Number of Subjects (8 to 12 Years of Age) Reporting Solicited Local and Systemic Adverse Events After Receiving Bexsero® Booster Vaccine.
Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.
Time frame: From day 1 (6 hr) through day 7 after vaccination
Number of Newly Recruited naïve Subjects (Aged 8 to 12 Years of Age) Solicited Local and Systemic Adverse Events After Receiving Bexsero® Vaccine.
The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.
Time frame: From day 1(6 hr) through day 7 after vaccination
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Bexsero® Vaccination.
The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.
Time frame: From day 1 through day 7 after any vaccination
Number of Subjects Reporting Unsolicited Serious Adverse Events (SAEs), Medically Attended AEs and AEs Leading to Withdrawal for Entire Study Period.
The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.
Time frame: Throughout the entire study period (up to 2 months)
Subjects were recruited from 9 study sites in Hungary and 8 study sites in Spain.
| Milestone | 2H3H511_V | 2H3H511_NV | 3H5_11_V | 3H5_11_NV | 68_11_V | 68_11_NV | 02_2_5_V | 02_2_5_NV | 02_6_10_V | 02_6_10_NV | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 98 | 47 | 89 | 43 | 81 | 39 | 32 | 36 | 91 | 90 | 100 | 55 | 50 |
| Completed | 96 | 47 | 89 | 43 | 78 | 39 | 32 | 36 | 91 | 89 | 98 | 55 | 50 |
| Not completed | 2 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other-unspecified | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules, is presented in terms of the percentage of subjects in each vaccine group, with hSBA titers ≥ 4 for what concerns the H44/76, 5/99 and NZ98/254 strains, and hSBA titers ≥ 5 for M10713 strain, alongside with the corresponding antibody responses in age-matched vaccine naïve subjects at baseline. The functional bactericidal antibodies directed against serogroup B meningococcal were assessed by the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).
| Percentage of subjects | 2H3H511 | 3H5_11 | 68_11 | NAIVE 123 | 02_2_5 | NAIVE_4A | 02_6_10 | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| H44/76 | 51 (42.8 to 60) | 53 (43.8 to 61.5) | 61 (52 to 70.1) | 38 (28.5 to 48.3) | 52 (39.7 to 64.6) | 27 (16.1 to 41) | 58 (50.3 to 65.2) | 20 (10 to 33.7) |
| 5/99 | 84 (77.2 to 89.9) | 88 (80.9 to 92.9) | 93 (87.2 to 97.1) | 3 (0.6 to 8.5) | 79 (67.4 to 88.1) | 4 (0.44 to 12.5) | 85 (79.4 to 90.3) | 8 (2.2 to 19.2) |
| NZ98/254 | 45 (36.6 to 53.6) | 38 (29.8 to 47.1) | 56 (46.9 to 65.4) | 2 (0.24 to 7) | 29 (19 to 41.7) | 7 (2 to 17.6) | 50 (42.2 to 57.3) | 6 (1.3 to 16.5) |
| M10713 | 31 (22.8 to 39.5) | 36 (27.1 to 45.7) | 39 (29.4 to 48.3) | 37 (26.8 to 47.2) | 34 (22.6 to 46.6) | 38 (24.8 to 52.1) | 61 (53.0 to 68.0) | 55 (40.2 to 69.3) |
The antibody persistence in subjects, 24 to 36 months after completion of Bexsero® vaccination course in the parent study according to different schedules is presented in terms of the percentage of subjects in each vaccine group with hSBA titers ≥ 8, alongside with the corresponding antibody responses in age matched vaccine naïve subjects at baseline.
| Percentage of subjects | 2H3H511 | 3H5_11 | 68_11 | NAIVE 123 | 02_2_5 | NAIVE_4A | 02_6_10 | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| H44/76 | 28 (20.6 to 36.1) | 26 (18.7 to 34.3) | 32 (23.7 to 41.1) | 18 (11 to 26.9) | 24 (14.3 to 35.9) | 16 (7.8 to 28.8) | 34 (26.8 to 41.2) | 10 (3.3 to 21.8) |
| 5/99 | 80 (72.4 to 86.3) | 82 (74.8 to 88.5) | 89 (82 to 94.1) | 2 (0.24 to 7) | 73 (60.9 to 83.2) | 4 (0.44 to 12.5) | 66 (59.1 to 73.3) | 6 (1.3 to 16.5) |
| NZ98/254 | 21 (14.9 to 29.2) | 18 (12.1 to 26) | 29 (20.7 to 37.6) | 0 (0 to 3.6) | 15 (7.3 to 25.4) | 2 (0.05 to 9.7) | 28 (21.5 to 35.1) | 0 (0 to 7.1) |
| M10713 | 24 (16.5 to 32) | 22 (14.4 to 30.4) | 28 (20.2 to 37.9) | 26 (17.3 to 35.9) | 31 (19.9 to 43.4) | 36 (23.1 to 50.2) | 54 (46 to 61.4) | 49 (34.4 to 63.7) |
The hSBA antibody titers in subjects, 24 to 36 months after completion of Bexsero® vaccination course according to different schedules in the parent study, are presented in terms of vaccine-group-specific GMTs, alongside with the corresponding antibody responses in age-matched vaccine-naïve subjects at baseline.
| Titers | 2H3H511 | 3H5_11 | 68_11 | NAIVE 123 | 02_2_5 | NAIVE_4A | 02_6_10 | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| H44/76 | 4.17 (3.4 to 5.13) | 4.48 (3.6 to 5.57) | 5.62 (4.48 to 7.04) | 2.79 (2.25 to 3.45) | 3.97 (2.99 to 5.28) | 2.33 (1.77 to 3.07) | 5.75 (4.78 to 6.91) | 1.93 (1.39 to 2.68) |
| 5/99 | 44 (32 to 60) | 52 (37 to 72) | 83 (58 to 117) | 1.15 (1.03 to 1.29) | 21 (14 to 33) | 1.2 (0.96 to 1.51) | 21 (16 to 28) | 1.38 (1.1 to 1.73) |
| NZ98/254 | 3.48 (2.78 to 4.36) | 2.98 (2.35 to 3.78) | 4.86 (3.8 to 6.22) | 1.14 (1.06 to 1.22) | 2.81 (2.07 to 3.82) | 1.37 (1.17 to 1.61) | 4.57 (3.74 to 5.59) | 1.22 (1.06 to 1.41) |
| M10713 | 2.77 (2.06 to 3.71) | 3.03 (2.2 to 4.16) | 3.17 (2.3 to 4.38) | 3.3 (2.52 to 4.32) | 3.53 (2.38 to 5.25) | 4.26 (2.61 to 6.97) | 7.82 (6.04 to 10) | 6.95 (4.18 to 12) |
The within-subjects GMR of GMTs at 24 to 36 months versus 1 month after completion of Bexsero® vaccination course according to different schedules vaccination in parent study are reported.
| Ratio | 2H3H511 | 3H5_11 | 68_11 | 02_2_5 | 02_6_10 |
|---|---|---|---|---|---|
| H44/76 | 0.029 (0.023 to 0.036) | 0.022 (0.017 to 0.028) | 0.03 (0.023 to 0.038) | 0.028 (0.021 to 0.038) | 0.042 (0.035 to 0.052) |
| 5/99 | 0.023 (0.017 to 0.03) | 0.031 (0.023 to 0.041) | 0.054 (0.04 to 0.073) | 0.045 (0.031 to 0.066) | 0.049 (0.038 to 0.063) |
| NZ98/254 | 0.059 (0.047 to 0.074) | 0.038 (0.03 to 0.048) | 0.07 (0.055 to 0.09) | 0.061 (0.044 to 0.083) | 0.095 (0.077 to 0.12) |
| M10713 | 0.19 (0.13 to 0.28) | 0.16 (0.11 to 0.25) | 0.19 (0.12 to 0.29) | 0.17 (0.11 to 0.28) | 0.24 (0.17 to 0.32) |
The within-subjects GMR of GMTs at 24 to 36 months versus visit 1 in the vaccination course according to different schedules vaccination in the parent study are reported.
| Ratio | 02_2_5 | 02_6_10 |
|---|---|---|
| H44/76 | 1.88 (1.32 to 2.69) | 2.94 (2.33 to 3.71) |
| 5/99 | 20 (12 to 32) | 14 (10 to 20) |
| NZ98/254 | 2.48 (1.76 to 3.49) | 3.06 (2.44 to 3.83) |
| M10713 | 0.89 (0.49 to 1.61) | 0.94 (0.64 to 1.37) |
The percentage of subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and with hSBA titers ≥ 5 against M10713 strain, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study), alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
| Percentage of subjects | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| H44/76 (pre-vacc.) | 48 (37.3 to 58.5) | 51 (40.1 to 62.1) | 64 (52.1 to 74.8) | 39 (21.8 to 57.8) | 59 (48.5 to 69.5) | 39 (28.8 to 49) | 27 (16.1 to 41) | 20 (10 to 33.7) |
| H44/76 (post-vacc.) | 99 (94.3 to 99.97) | 100 (95.8 to 100) | 100 (95.2 to 100) | 97 (83.8 to 99.92) | 99 (94 to 99.97) | 95 (88.3 to 98.3) | 91 (80 to 97) | 80 (66.3 to 90) |
| 5/99 (pre-vacc.) | 84 (74.5 to 90.6) | 91 (82.7 to 95.9) | 95 (87.1 to 98.5) | 74 (55.4 to 88.1) | 86 (76.8 to 92.2) | 3 (0.6 to 8.9) | 4 (0.44 to 12.5) | 8 (2.2 to 19.2) |
| 5/99 (post-vacc.) | 99 (94.3 to 99.97) | 99 (93.8 to 99.97) | 97 (90.8 to 99.68) | 100 (89.1 to 100) | 100 (96 to 100) | 88 (79.2 to 93.4) | 93 (82.4 to 98) | 80 (66.3 to 90) |
| NZ98/254 (pre-vacc.) | 45 (34.2 to 55.3) | 42 (31.3 to 53) | 52 (40.2 to 63.7) | 25 (11.5 to 43.4) | 47 (36.7 to 58) | 2 (0.25 to 7.3) | 7 (2.1 to 17.9) | 6 (1.3 to 16.5) |
| NZ98/254 (post-vacc.) | 99 (94.3 to 99.97) | 100 (95.8 to 100) | 100 (95.2 to 100) | 100 (89.1 to 100) | 100 (96 to 100) | 78 (68.5 to 85.9) | 85 (72.9 to 93.4) | 70 (55.4 to 82.1) |
| M10713 (pre-vacc.) | 36 (25.3 to 47.6) | 35 (24.1 to 47.8) | 45 (32.3 to 57.5) | 21 (8 to 39.7) | 63 (52.2 to 73.3) | 39 (28.8 to 50.5) | 41 (27 to 55.8) | 59 (43.2 to 73) |
| M10713 (post-vacc.) | 70 (59.8 to 79.7) | 81 (70.6 to 89) | 97 (89.6 to 99.64) | 97 (77.9 to 99.2) | 96 (88.9 to 98.8) | 47 (35.9 to 57.5) | 59 (44.2 to 72.4) | 60 (44.3 to 73.6) |
The percentage of subjects with hSBA titers ≥ 8, after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
| Percentage of subjects | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| H44/76 (pre-vacc.) | 26 (17.5 to 36.3) | 31 (21.8 to 42.3) | 33 (22.9 to 45.2) | 19 (7.5 to 37.5) | 30 (20.5 to 40.2) | 18 (10.7 to 26.8) | 16 (7.8 to 28.8) | 10 (3.3 to 21.8) |
| H44/76 (post-vacc.) | 97 (91.1 to 99.4) | 98 (91.9 to 99.72) | 99 (92.8 to 99.97) | 97 (83.8 to 99.92) | 97 (90.7 to 99.3) | 68 (57.4 to 76.9) | 71 (57.1 to 82.4) | 60 (45.2 to 73.6) |
| 5/99 (pre-vacc.) | 79 (69.6 to 87.1) | 85 (75.8 to 91.8) | 91 (81.9 to 96.2) | 71 (52 to 85.8) | 68 (57.5 to 77.5) | 2 (0.25 to 7.3) | 4 (0.44 to 12.5) | 6 (1.3 to 16.5) |
| 5/99 (post-vacc.) | 99 (94.3 to 99.97) | 99 (93.8 to 99.97) | 97 (90.8 to 99.68) | 100 (89.1 to 100) | 100 (96 to 100) | 77 (67.4 to 85) | 78 (65 to 88.2) | 60 (45.2 to 73.6) |
| NZ98/254 (pre-vacc.) | 22 (13.8 to 31.6) | 19 (11 to 28.4) | 28 (18.2 to 39.6) | 13 (3.5 to 29) | 26 (17.7 to 36.7) | 0 (0 to 3.8) | 2 (0.05 to 9.9) | 0 (0 to 7.1) |
| NZ98/54 (post-vacc.) | 97 (91.1 to 99.4) | 98 (91.9 to 99.72) | 100 (95.2 to 100) | 97 (83.8 to 99.92) | 97 (90.7 to 99.3) | 34 (25 to 44.8) | 54 (39.6 to 67.4) | 40 (26.4 to 54.8) |
| M10713 (pre-vacc.) | 28 (18.6 to 39.5) | 22 (12.9 to 33.8) | 34 (22.6 to 46.6) | 17 (5.8 to 35.8) | 55 (44.1 to 65.9) | 27 (18.2 to 38.2) | 39 (25.2 to 53.8) | 52 (36.9 to 67.1) |
| M10713 (post-vacc.) | 64 (52.7 to 73.6) | 71 (59.6 to 80.6) | 94 (85.4 to 98.3) | 90 (73.5 to 97.9) | 92 (84.5 to 96.8) | 34 (24.3 to 45) | 51 (36.6 to 65.2) | 57 (42.2 to 71.7) |
The percentage of subjects with a four-fold rise in hSBA titers 1 month after receiving Bexsero® booster vaccination in this study to pre vaccination at visit 1 (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
| Percentage of subjects | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| H44/76 (Day 31/PRE) | 95 (87.8 to 98.2) | 95 (88.5 to 98.7) | 97 (90.7 to 99.68) | 94 (78.6 to 99.2) | 97 (90.7 to 99.3) | 43 (32.7 to 53.2) | 53 (38.8 to 66.3) | 46 (31.8 to 60.7) |
| 5/99 (Day 31/PRE) | 98 (92.4 to 99.74) | 98 (91.9 to 99.72) | 95 (87.1 to 98.5) | 100 (88.8 to 100) | 98 (92.3 to 99.73) | 77 (67.4 to 85) | 76 (63 to 86.8) | 60 (45.2 to 73.6) |
| NZ98/254 (Day 31/PRE) | 92 (84.9 to 96.9) | 95 (88.5 to 98.7) | 93 (85.1 to 97.8) | 94 (79.2 to 99.2) | 86 (76.8 to 92.2) | 34 (25 to 44.8) | 54 (39.6 to 67.4) | 40 (26.4 to 54.8) |
| M10713 (Day 31/PRE) | 41 (30 to 52.7) | 50 (37.6 to 62.4) | 68 (54.9 to 78.8) | 72 (52.8 to 87.3) | 53 (41.9 to 63.7) | 11 (5 to 19.4) | 20 (10.2 to 34.3) | 13 (4.9 to 26.3) |
The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination (visit 2) in this study to post primary visit in the parent study V72_28(1 month after last vaccination in the parent study) alongside the corresponding response after the first dose of Bexsero® vaccine in age matched vaccine-naïve subjects.
| Percentage of subjects | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V |
|---|---|---|---|---|---|
| H44/76 | 5 (1.7 to 12.0) | 5 (1.3 to 11.7) | 13 (6.6 to 23.2) | 22 (9.3 to 40.0) | 17 (9.9 to 26.6) |
| 5/99 | 19 (11.9 to 28.9) | 27 (17.8 to 37.4) | 37 (26.1 to 48.7) | 66 (46.8 to 81.4) | 72 (61.4 to 80.9) |
| NZ98/254 | 25 (16.4 to 34.8) | 15 (8.5 to 25.0) | 27 (17.6 to 39.1) | 13 (3.5 to 29.0) | 18 (10.8 to 27.8) |
| M10713 | 15 (7.7 to 25.0) | 21 (11.4 to 33.9) | 24 (13.1 to 38.2) | 21 (8.0 to 39.7) | 11 (5.2 to 20.0) |
The percentage of subjects with a four-fold rise in hSBA titers one month after receiving Bexsero® booster vaccination in this study to pre primary visit in parent study V72_28 (Visit 1). This outcome measure was analysed only for subjects belonging to groups 02_2_5_V and 02_6_10_V
| Percentage of subjects | 02_2_5_V | 02_6_10_V |
|---|---|---|
| H44/76 | 97 (83.8 to 99.92) | 96 (89.1 to 98.8) |
| 5/99 | 100 (89.1 to 100.0) | 100 (96.0 to 100.0) |
| NZ98/254 | 94 (78.6 to 99.2) | 97 (90.6 to 99.3) |
| M10713 | 67 (46.0 to 83.5) | 55 (43.5 to 65.9) |
The hSBA antibody titers in subjects after receiving Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the corresponding response after the 1st dose of Bexsero® vaccine in age matched vaccine-naïve subjects in terms of GMTs.
| Titers | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| The GMTs Against N.Meningitidis Serogroup B, One Month After Receiving Bexsero® Booster Vaccination in the Present Study. | 3.91 (3.01 to 5.08) | 4.84 (3.66 to 6.41) | 6.21 (4.65 to 8.31) | 3.14 (2.08 to 4.75) | 6.15 (4.77 to 7.93) | 2.82 (2.26 to 3.5) | 2.33 (1.77 to 3.07) | 1.93 (1.39 to 2.68) |
The within-subjects GMR of hSBA antibody titers (one month post booster vaccination versus pre vaccination) after Bexsero® booster vaccination in this study (24 to 36 months after completion of vaccination course according to different schedules in parent study) alongside the within-subject GMR for the 1st dose of rMenB+OMV NZ vaccination of age matched naïve subjects.
| Ratio | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| H44/76 (Day 31/PRE) | 41 (30 to 55) | 43 (31 to 59) | 46 (33 to 65) | 50 (31 to 80) | 42 (31 to 56) | 4.81 (3.81 to 6.07) | 7.08 (5.07 to 9.88) | 6.87 (4.62 to 10) |
| 5/99 (Day 31/PRE) | 75 (54 to 104) | 67 (47 to 96) | 41 (29 to 60) | 160 (95 to 270) | 135 (98 to 186) | 34 (24 to 46) | 22 (15 to 34) | 14 (9.11 to 23) |
| NZ98/254 (Day 31/PRE) | 28 (20 to 38) | 29 (21 to 41) | 27 (19 to 39) | 24 (15 to 40) | 18 (13 to 25) | 6.07 (4.97 to 7.41) | 9.58 (6.8 to 13) | 7.01 (4.54 to 11) |
| M10713 (Day 31/PRE) | 4.07 (2.8 to 5.91) | 5.65 (3.77 to 8.47) | 11 (7.15 to 16) | 13 (7.29 to 23) | 6.85 (4.86 to 9.66) | 1.38 (1.01 to 1.88) | 2.06 (1.36 to 3.12) | 1.55 (1.1 to 2.18) |
The within-subjects GMR of hSBA antibody titers (one month post booster vaccination in this study versus 1 month post last vaccination visit (post-primary vaccination visit) in parent study V72_28.
| Ratio | 2H3H511_V | 3H5_11_V | 68_11_V |
|---|---|---|---|
| H44/76 | 1.06 (0.82 to 1.38) | 0.90 (0.68 to 1.20) | 1.37 (1.02 to 1.84) |
| 5/99 | 1.60 (1.20 to 2.13) | 2.07 (1.52 to 2.82) | 2.33 (1.69 to 3.20) |
| NZ98/254 | 1.66 (1.25 to 2.20) | 1.10 (0.81 to 1.49) | 1.75 (1.28 to 2.41) |
| M10713 | 1.01 (0.65 to 1.58) | 1.37 (0.82 to 2.29) | 2.35 (1.37 to 4.02) |
The percentage of vaccine-naïve subjects with hSBA titers ≥ 4 against H44/76, 5/99 and NZ98/254 strains, and ≥ 5 against M10713 strain, one month after receiving two catch up doses of Bexsero® booster vaccination in this study.
| Percentage of subjects | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|
| H44/76 (baseline) | 38 (28.2 to 48.1) | 26 (15 to 39.7) | 20 (10.2 to 34.3) |
| H44/76 (Day 61) | 100 (96.3 to 100) | 98 (90.1 to 99.95) | 100 (92.7 to 100) |
| 5/99 (baseline) | 3 (0.6 to 8.7) | 4 (0.45 to 12.7) | 6 (1.3 to 16.9) |
| 5/99 (Day 61) | 100 (96.3 to 100) | 100 (93.4 to 100) | 100 (92.7 to 100) |
| NZ98/254 (baseline) | 2 (0.25 to 7.2) | 7 (2.1 to 17.9) | 6 (1.3 to 17.2) |
| NZ98/254 (Day 61) | 100 (96.3 to 100) | 100 (93.4 to 100) | 100 (92.6 to 100) |
| M10713 (baseline) | 34 (24.6 to 45.4) | 40 (26.4 to 54.8) | 55 (40.2 to 69.3) |
| M10713 (Day 61) | 75 (64.5 to 83.3) | 69 (54.9 to 81.3) | 76 (61.1 to 86.7) |
The percentage of vaccine-naïve subjects with hSBA titers ≥8, one month after receiving two catch up doses of Bexsero® booster vaccination in this study are reported.
| Percentage of subjects | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|
| H44/76 (baseline) | 17 (10.4 to 26.3) | 15 (6.6 to 27.1) | 10 (3.4 to 22.2) |
| H44/76 (Day 61) | 99 (94.4 to 99.97) | 96 (87.3 to 99.55) | 98 (89.1 to 99.95) |
| 5/99 (baseline) | 2 (0.25 to 7.2) | 4 (0.45 to 12.7) | 4 (0.5 to 14) |
| 5/99 (Day 61) | 100 (96.3 to 100) | 100 (93.4 to 100) | 98 (89.1 to 99.95) |
| NZ98/254 (baseline) | 0 (0 to 3.7) | 2 (0.05 to 9.9) | 0 (0 to 7.4) |
| NZ98/254 (Day 61) | 96 (89.9 to 98.9) | 93 (82.1 to 97.9) | 94 (82.8 to 98.7) |
| M10713 (baseline) | 25 (16.6 to 35.7) | 38 (24.7 to 52.8) | 49 (34.4 to 63.7) |
| M10713 (Day 61) | 65 (54.1 to 74.6) | 63 (49 to 76.4) | 69 (54.6 to 81.7) |
The percentage of vaccine-naïve subjects with a four-fold rise in hSBA titers from baseline, one month after receiving two catch up doses of Bexsero® booster vaccination in comparison to prevaccination in this study are reported.
| Percentage of subjects | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|
| H44/76 | 94 (87.1 to 97.7) | 89 (77.4 to 95.8) | 94 (83.1 to 98.7) |
| 5/99 | 100 (96.3 to 100) | 100 (93.4 to 100) | 98 (89.1 to 99.95) |
| NZ98/254 | 94 (87.1 to 97.7) | 91 (79.7 to 96.9) | 94 (82.8 to 98.7) |
| M10713 | 37 (26.7 to 47.8) | 28 (16.2 to 42.5) | 22 (11.8 to 36.6) |
The hSBA antibody titers in vaccine-naïve subjects , after receiving two catch up doses of Bexsero® vaccination in this study, are reported in terms of GMTs.
| Titers | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|
| H44/76 (baseline) | 2.3 (1.75 to 3.01) | 2.15 (1.55 to 3) | 1.56 (1.11 to 2.2) |
| H44/76 (Day 61) | 107 (84 to 135) | 74 (56 to 99) | 63 (47 to 85) |
| 5/99 (baseline) | 1.13 (0.94 to 1.36) | 1.13 (0.9 to 1.41) | 1.31 (1.04 to 1.65) |
| 5/99 (Day 61) | 631 (503 to 792) | 421 (319 to 555) | 317 (238 to 423) |
| NZ98/254 (baseline) | 1.11 (0.98 to 1.26) | 1.34 (1.15 to 1.56) | 1.2 (1.02 to 1.4) |
| NZ98/254 (Day 61) | 34 (27 to 42) | 37 (28 to 49) | 34 (26 to 46) |
| M10713 (baseline) | 2.9 (1.94 to 4.34) | 4.12 (2.54 to 6.69) | 6.4 (3.91 to 10) |
| M10713 (Day 61) | 12 (7.57 to 18) | 11 (6.87 to 19) | 14 (8.34 to 24) |
The within-subject GMRs of hSBA titers at one month after receiving the second catch up dose to hSBA titers at baseline, for naïve subjects who received two catch up doses of Bexsero® vaccination in this study are reported.
| Ratio | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|
| H44/76 | 46 (34 to 63) | 34 (24 to 50) | 41 (27 to 60) |
| 5/99 | 558 (423 to 737) | 373 (266 to 524) | 242 (171 to 344) |
| NZ98/254 | 30 (24 to 39) | 27 (20 to 37) | 29 (21 to 39) |
| M10713 | 3.86 (2.62 to 5.69) | 2.93 (1.84 to 4.67) | 2.2 (1.37 to 3.53) |
The number of subjects (35 months to 7 years of age) with solicited local and systemic adverse events after receiving Bexsero® booster vaccine in the present study.
| Subjects | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V |
|---|---|---|---|---|
| Any local AEs | 87 | 81 | 73 | 31 |
| Erythema | 60 | 63 | 42 | 22 |
| Induration | 48 | 48 | 33 | 15 |
| Swelling | 49 | 50 | 37 | 20 |
| Tenderness | 84 | 80 | 71 | 31 |
| Any systemic AEs | 66 | 63 | 54 | 18 |
| Change in eating habits | 31 | 32 | 30 | 5 |
| Diarrhea | 4 | 8 | 5 | 0 |
| Irritability | 54 | 52 | 46 | 9 |
| Persistent Crying | 31 | 24 | 25 | 4 |
| Rash | 13 | 1 | 3 | 5 |
| Sleepiness | 28 | 23 | 26 | 5 |
| Vomiting | 5 | 5 | 2 | 1 |
| Fever (>38.0° C) | 17 | 18 | 11 | 2 |
| Medically-Attended Fever | 1 | 0 | 2 | 0 |
| Prevention of Pain and/or Fever | 23 | 14 | 15 | 1 |
| Treatment of Pain and/or Fever | 38 | 39 | 41 | 13 |
The number of newly recruited subjects (aged 35 months to 7 years) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.
| Subjects | NAIVE 123 | NAIVE_4A |
|---|---|---|
| Any local AEs (1st vacc.) | 88 | 55 |
| Erythema (1st vacc.) | 54 | 28 |
| Induration (1st vacc.) | 38 | 17 |
| Swelling (1st vacc.) | 40 | 24 |
| Tenderness (1st vacc.) | 87 | 55 |
| Any systemic AEs (1st vacc.) | 64 | 24 |
| Change in Eating Habits (1st vacc.) | 31 | 5 |
| Diarrhea (1st vacc.) | 4 | 3 |
| Irritability (1st vacc.) | 40 | 16 |
| Persistent Crying (1st vacc.) | 15 | 4 |
| Rash (1st vacc.) | 5 | 3 |
| Sleepiness (1st vacc.) | 18 | 9 |
| Vomiting (1st vacc.) | 7 | 2 |
| Fever (>38.0° C) (1st vacc.) | 15 | 2 |
| Medically-Attended Fever (1st vacc.) | 1 | 0 |
| Prevention of Pain/Fever (1st vacc.) | 18 | 3 |
| Treatment of Pain/Fever (1st vacc.) | 41 | 22 |
| Any local AEs (2nd vacc.) | 79 | 51 |
| Erythema (2nd vacc.) | 44 | 32 |
| Induration (2nd vacc.) | 29 | 22 |
| Swelling (2nd vacc.) | 32 | 25 |
| Tenderness (2nd vacc.) | 77 | 51 |
| Any systemic AEs (2nd vacc.) | 46 | 18 |
| Change in Eating Habits (2nd vacc.) | 15 | 9 |
| Diarrhea (2nd vacc.) | 2 | 3 |
| Irritability (2nd vacc.) | 25 | 11 |
| Persistent Crying (2nd vacc.) | 13 | 6 |
| Rash (2nd vacc.) | 2 | 1 |
| Sleepiness (2nd vacc.) | 12 | 5 |
| Vomiting (2nd vacc.) | 4 | 2 |
| Fever (>38.0° C) (2nd vacc.) | 12 | 3 |
| Medically-Attended Fever (2nd vacc.) | 0 | 1 |
| Prevention of Pain/Fever (2nd vacc.) | 21 | 4 |
| Treatment of Pain/Fever (2nd vacc.) | 30 | 13 |
Number of subjects (8 to 12 years of age) reporting solicited local and systemic adverse events after receiving Bexsero® booster vaccine.
| Subjects | 02_6_10_V |
|---|---|
| Any local AEs | 85 |
| Erythema | 57 |
| Induration | 44 |
| Swelling | 52 |
| Pain | 84 |
| Any systemic AEs | 57 |
| Arthralgia | 18 |
| Chills | 23 |
| Headache | 27 |
| Malaise | 35 |
| Myalgia | 24 |
| Nausea | 12 |
| Rash | 10 |
| Fever (>38.0° C) | 10 |
| Medically-Attended Fever | 0 |
| Prevention of Pain and/or Fever | 12 |
| Treatment of Pain and/or Fever | 47 |
The number newly recruited naïve subjects (aged 8 to12 years of age) reporting solicited local and systemic adverse events after receiving two catch-up doses of Bexsero® vaccine in the present study.
| Subjects | NAIVE_4B |
|---|---|
| Any local AEs (1st vacc.) | 49 |
| Erythema (1st vacc.) | 31 |
| Induration (1st vacc.) | 19 |
| Swelling (1st vacc.) | 29 |
| Pain (1st vacc.) | 47 |
| Any systemic AEs (1st vacc.) | 24 |
| Arthralgia (1st vacc.) | 6 |
| Chills (1st vacc.) | 4 |
| Headache (1st vacc.) | 15 |
| Malaise (1st vacc.) | 7 |
| Myalgia (1st vacc.) | 12 |
| Nausea (1st vacc.) | 5 |
| Rash (1st vacc.) | 1 |
| Fever (>38.0° C) (1st vacc.) | 3 |
| Medically-Attended Fever (1st vacc.) | 0 |
| Prevention of Pain and/or Fever (1st vacc.) | 2 |
| Treatment of Pain and/or Fever (1st vacc.) | 21 |
| Any local AEs (2nd vacc.) | 43 |
| Erythema (2nd vacc.) | 21 |
| Induration (2nd vacc.) | 17 |
| Swelling (2nd vacc.) | 21 |
| Pain (2nd vacc.) | 41 |
| Any systemic AEs (2nd vacc.) | 25 |
| Arthralgia (2nd vacc.) | 3 |
| Chills (2nd vacc.) | 5 |
| Headache (2nd vacc.) | 10 |
| Malaise (2nd vacc.) | 13 |
| Myalgia (2nd vacc.) | 8 |
| Nausea (2nd vacc.) | 4 |
| Rash (2nd vacc.) | 3 |
| Fever (>38.0° C) (2nd vacc.) | 1 |
| Medically-Attended Fever (2nd vacc.) | 0 |
| Prevention of Pain and/or Fever (2nd vacc.) | 3 |
| Treatment of Pain and/or Fever (2nd vacc.) | 12 |
The number of subjects reporting unsolicited adverse events after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in parent study) or two cach up schedule of Bexsero® vaccine is reported.
| Subjects | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| Any AEs | 26 | 19 | 26 | 9 | 14 | 43 | 25 | 12 |
| Possibly or Probably Related AEs | 9 | 7 | 10 | 6 | 11 | 12 | 10 | 6 |
| AEs leading to Premature Withdrawal | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The number of subjects reporting unsolicited SAEs, medically attended AEs and AEs leading to withdrawal after receiving Bexsero® booster vaccination (24 to 36 months after completion of vaccination course according to different schedules in the parent study) or two catch-up schedule of Bexsero® vaccine is reported.
| Subjects | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| Any SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Possibly or probably related SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Solicited and unsolicited AEs were collected from Day 1 (30 minutes) throughout Day 7; SAEs were collected throughout the entire study period (up to 2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2H3H511_V | 0/97 (0%) | 0/97 (0%) | 91/97 (93.8%) |
| 3H5_11_V | 0/89 (0%) | 0/89 (0%) | 84/89 (94.4%) |
| 68_11_V | 0/80 (0%) | 0/80 (0%) | 75/80 (93.8%) |
| 02_2_5_V | 0/32 (0%) | 0/32 (0%) | 31/32 (96.9%) |
| 02_6_10_V | 0/91 (0%) | 0/91 (0%) | 86/91 (94.5%) |
| NAIVE 123 | 0/100 (0%) | 0/100 (0%) | 97/100 (97%) |
| NAIVE_4A | 0/55 (0%) | 0/55 (0%) | 55/55 (100%) |
| NAIVE_4B | 0/50 (0%) | 0/50 (0%) | 50/50 (100%) |
| Event | 2H3H511_V | 3H5_11_V | 68_11_V | 02_2_5_V | 02_6_10_V | NAIVE 123 | NAIVE_4A | NAIVE_4B |
|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 84/96 | 80/89 | 71/78 | 31/32 | 84/91 | 94/100 | 55/55 | 48/50 |
| Injection site erythemaGeneral disorders | 61/96 | 63/89 | 42/78 | 22/32 | 57/91 | 65/100 | 38/55 | 37/50 |
| Injection site swellingGeneral disorders | 49/96 | 50/89 | 37/78 | 20/32 | 52/91 | 51/100 | 36/55 | 34/50 |
| IrritabilityPsychiatric disorders | 54/96 | 52/89 | 46/78 | 9/32 | 0/91 | 48/100 | 19/55 | 1/50 |
| Injection site indurationGeneral disorders | 48/96 | 48/89 | 33/78 | 15/32 | 44/91 | 48/100 | 28/55 | 25/50 |
| HeadacheNervous system disorders | 0/96 | 0/89 | 0/78 | 0/32 | 27/91 | 0/100 | 1/55 | 20/50 |
| MalaiseGeneral disorders | 0/96 | 0/89 | 0/78 | 0/32 | 35/91 | 0/100 | 0/55 | 16/50 |
| Eating disorderPsychiatric disorders | 31/96 | 32/89 | 30/78 | 5/32 | 0/91 | 36/100 | 13/55 | 0/50 |
| SomnolenceNervous system disorders | 28/96 | 23/89 | 26/78 | 5/32 | 0/91 | 23/100 | 10/55 | 0/50 |
| CryingGeneral disorders | 31/96 | 24/89 | 25/78 | 4/32 | 0/91 | 23/100 | 8/55 | 0/50 |
| Age, Continuous(Years) | 2H3H511_V | 2H3H511_NV | 3H5_11_V | 3H5_11_NV | 68_11_V | 68_11_NV | 02_2_5_V | 02_2_5_NV | 02_6_10_V | 02_6_10_NV | NAIVE 123 | NAIVE_4A | NAIVE_4B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 3.1 ± 0.2 | 3 ± 0.18 | 3.1 ± 0.23 | 3.1 ± 0.22 | 3.2 ± 0.29 | 3.2 ± 0.26 | 6.5 ± 1.15 | 6.7 ± 1.16 | 10.4 ± 1.43 | 10.4 ± 1.44 | 3.4 ± 0.29 | 5.8 ± 1.12 | 9.7 ± 1.38 | 5.6 ± 3.20 |
| Sex: Female, Male(Participants) | 2H3H511_V | 2H3H511_NV | 3H5_11_V | 3H5_11_NV | 68_11_V | 68_11_NV | 02_2_5_V | 02_2_5_NV | 02_6_10_V | 02_6_10_NV | NAIVE 123 | NAIVE_4A | NAIVE_4B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 44 | 27 | 48 | 22 | 35 | 23 | 19 | 15 | 44 | 46 | 46 | 26 | 27 | 422 |
| Male | 54 | 20 | 41 | 21 | 46 | 16 | 13 | 21 | 47 | 44 | 54 | 29 | 23 | 429 |
The record gives a start of Jun 2013, a primary completion of Sep 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2018, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.